SEARCH:   Advanced

Blood, 1 June 2005, Vol. 105, No. 11, pp. 4532-4539. Prepublished online as a Blood First Edition Paper on February 24, 2005; DOI 10.1182/blood-2004-06-2387. This Article Full Text (PDF) All Versions of this Article: 2004-06-2387v1 105/11/4532    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Crawley, C. Articles by Apperley, J. F Search for Related Content PubMed PubMed Citation Articles by Crawley, C. Articles by Apperley, J. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 23, 2004 Accepted January 11, 2005 Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT Charles Crawley*, Marc Lalancette, Richard Szydlo, Maria Gilleece, Karl Peggs, Stephen Mackinnon, Gunnar Juliusson, Lucia Ahlberg, Arnon Nagler, Avichai Shimoni, Anna Sureda, Jean-Michel Boiron, Herman Einsele, Rajesh Chopra, Angelo Carella, Jamie Cavenagh, Alois Gratwohl, Frederic Garban, Axel Zander, Bo Bjorkstrand, Dietger Niederwieser, Gosta Gahrton, and Jane F Apperley Addenbrookes Hospital, Cambridge, United Kingdom CHUQ L'Hotel-Dieu, Quebec, Canada Imperial College, Hammersmith Hospital, London, United Kingdom Ysbyty Gwynedd, Bangor, United Kingdom University College London, London, United Kingdom University Hospital, Lund, Sweden University Hospital, Linkoping, Sweden Chaim Sheba Medical Center, Tel-Hashomer, Israel Hospital Santa Creu i Sant Pau, Barcelona, Spain Universite Bordeaux 2 V Segalen & Etablissement Francais du Sang-AL, Bordeaux, France Medizinische Klinik and Poliklinik II, Wurzburg, Germany Christie Hospital, Manchester, United Kingdom Azienda Ospedaliera San Martino, Genoa, Italy St. Bartholomew's &The Royal London Hospital, London, United Kingdom Kantonsspital, Basel, Switzerland Hopital A. Michallon, Grenoble, France University Hospital Eppendorf, Hamburg, Germany Karolinska University Hospital, Stockholm, Sweden University of Leipzig, Leipzig, Germany * Corresponding author; email: charles.crawley{at}addenbrookes.nhs.uk. We report the outcome of 229 patients allografted for myeloma with reduced intensity conditioning regimens (RIC) from 33 centers within the European Group for Blood and Marrow Transplantation. The median age was 52 yrs and 64% were male. Conditioning regimens were heterogeneous but most were fludarabine based and T cell depleted with anti-thymocyte globulin or alemtuzumab. Transplant related mortality (TRM) at 1 year was 22%. The 3 year overall (OS) and progression free survivals (PFS) were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease (RR 2.9), >1 prior transplant (RR 2.0) and male patients with female donors (RR 1.45). Adverse PFS was associated with chemoresistance (RR 2.4), and alemtuzumab (RR 1.8). TRM was increased with female to male donation (RR 2.5) and transplant more than one year from diagnosis (RR 2.3). Grade II-IV aGvHD occurred in 31%. Chronic GvHD was associated with better OS and PFS and were 84% and 46% for limited, 58% and 30% for extensive and 29% and 12% in its absence suggesting that a graft vs myeloma effect is important. Whilst RIC is feasible, heavily pretreated patients and those with progressive disease do not benefit. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood, October 8, 2009; 114(15): 3276 - 3284. [Abstract] [Full Text] [PDF] L. Rosinol, J. A. Perez-Simon, A. Sureda, J. de la Rubia, F. de Arriba, J. J. Lahuerta, J. D. Gonzalez, J. Diaz-Mediavilla, B. Hernandez, J. Garcia-Frade, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Blood, November 1, 2008; 112(9): 3591 - 3593. [Abstract] [Full Text] [PDF] O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood, October 15, 2008; 112(8): 3362 - 3372. [Abstract] [Full Text] [PDF] S. V. Rajkumar Treatment of Myeloma: Cure vs Control Mayo Clin. Proc., October 1, 2008; 83(10): 1142 - 1145. [Full Text] [PDF] E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H.-G. Ljunggren, and M. S. Dilber Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components Blood, March 15, 2008; 111(6): 3155 - 3162. [Abstract] [Full Text] [PDF] G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma Haematologica, November 1, 2007; 92(11): 1513 - 1518. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] M. Cavo Nonmyeloablative allotransplantation for myeloma: light and shade Blood, April 15, 2007; 109(8): 3134 - 3135. [Full Text] [PDF] C. Crawley, S. Iacobelli, B. Bjorkstrand, J. F. Apperley, D. Niederwieser, G. Gahrton, and for the Chronic Leukaemia Working Party of the Eur Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning Blood, April 15, 2007; 109(8): 3588 - 3594. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, C. Smith, J. Z. Gong, A. Lagoo, et al. Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution J. Clin. Oncol., February 20, 2007; 25(6): 690 - 697. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF] S. Singhal and J. Mehta Multiple Myeloma Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1322 - 1330. [Abstract] [Full Text] [PDF] F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al. Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation J. Clin. Oncol., September 1, 2006; 24(25): 4150 - 4157. [Abstract] [Full Text] [PDF] F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood, May 1, 2006; 107(9): 3474 - 3480. [Abstract] [Full Text] [PDF] S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood, March 15, 2006; 107(6): 2578 - 2584. [Abstract] [Full Text] [PDF] M. Haubitz and D. Peest Myeloma - new approaches to combined nephrological-haematological management Nephrol. Dial. Transplant., March 1, 2006; 21(3): 582 - 590. [Full Text] [PDF] S. Giralt Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years? Hematology, January 1, 2005; 2005(1): 384 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020